Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease

Wood, Lindy; Neumiller, Joshua J.; Setter, Stephen M.; Dobbins, Erin K.

doi:10.1016/j.amjopharm.2010.08.002

Cited by 65 publications

(52 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This early form is referred to as mild cognitive impairment, a terminology utilized in the Alzheimer literature as well. The reported prevalence of cognitive decline in PD is highly variable, ranging from 10 to 90%, while dementia affects about 30-40% of PD patients, although some studies indicate that dementia is as frequent as nearly 80% (Aarsland et al, 2002;Wood et al, 2010). The risk of dementia significantly increases with age.…”

Section: Therapeutics For Nonmotor Symptoms Of Pdmentioning

confidence: 99%

“…All of the therapeutic approaches outlined above aim at treating the dopaminergic motor symptoms of PD, which remain the current focus of therapy development. However, it is clear that PD pathology extends far beyond the dopaminergic nigrostriatal system, and that nonmotor symptoms such as cognitive impairment, dementia, depression, psychosis, and autonomic dysfunction significantly contribute to the complex battery of deficits PD patients face, even at early stages of the disease (Chaudhuri et al, 2006(Chaudhuri et al, , 2011Chaudhuri and Schapira, 2009;Kasten et al, 2010;Lim and Lang, 2010;Poewe, 2010;Wood et al, 2010;Bassetti, 2011) (Table 3). Because most of these symptoms do not respond to, but are often exacerbated by, the traditional dopamine replacement therapy and STN DBS, the development of pharmacotherapy that could alleviate these nonmotor symptoms, while being effective in reducing parkinsonian motor signs, represents one of the most important challenges both basic and clinical PD scientists may face in the years to come.…”

Section: /1989mentioning

confidence: 99%

“…Because of space limitations, we will not provide an extensive account of the previous literature in this field, but rather focus on a few promising research avenues that may have a significant impact in the improvement of PD therapeutics in the years to come. Reflecting the limited availability of specific treatments for the nonmotor features in PD (Chaudhuri et al, 2006;Chaudhuri and Schapira, 2009;Lim and Lang, 2010;Wood et al, 2010), this review will mainly focus on the treatment of the parkinsonian motor symptoms induced by degeneration of midbrain dopaminergic neurons. A summary of the main PD therapeutic approaches that will be discussed in this review is illustrated in Figure 2.…”

Section: /1989mentioning

confidence: 99%

See 2 more Smart Citations

Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa

Smith

Wichmann

Factor

et al. 2011

Neuropsychopharmacol

196

137

View full text Add to dashboard Cite

The demonstration that dopamine loss is the key pathological feature of Parkinson's disease (PD), and the subsequent introduction of levodopa have revolutionalized the field of PD therapeutics. This review will discuss the significant progress that has been made in the development of new pharmacological and surgical tools to treat PD motor symptoms since this major breakthrough in the 1960s. However, we will also highlight some of the challenges the field of PD therapeutics has been struggling with during the past decades. The lack of neuroprotective therapies and the limited treatment strategies for the nonmotor symptoms of the disease (ie, cognitive impairments, autonomic dysfunctions, psychiatric disorders, etc.) are among the most pressing issues to be addressed in the years to come. It appears that the combination of early PD nonmotor symptoms with imaging of the nigrostriatal dopaminergic system offers a promising path toward the identification of PD biomarkers, which, once characterized, will set the stage for efficient use of neuroprotective agents that could slow down and alter the course of the disease.

show abstract

Section: Therapeutics For Nonmotor Symptoms Of Pdmentioning

confidence: 99%

Section: /1989mentioning

confidence: 99%

Section: /1989mentioning

confidence: 99%

See 1 more Smart Citation

Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa

Smith

Wichmann

Factor

et al. 2011

Neuropsychopharmacol

196

137

View full text Add to dashboard Cite

show abstract

“…This, coupled with the emphasis placed on the motor symptomatology of PD, has led to the non-motor complications gaining a relatively late entry into the field of treatment research. Notwithstanding this, in the past few decades a greater emphasis has been placed on non-motor symptoms with new treatment avenues being identified (Wood et al, 2010). …”

Section: Introductionmentioning

confidence: 99%

A systematic review of treatments for Impulse Control Disorders and related behaviours in Parkinson׳s disease

Tanwani

Fernie

Nikčević

et al. 2015

Psychiatry Research

View full text Add to dashboard Cite

Impulse Control Disorders (ICDs) are a set of behaviours characterised by impulsivity despite known harm. Related to ICDs is the dopamine dysregulation syndrome (DDS), which is characterised by an addiction-like consumption of dopaminergic medication and punding.These behaviours all have an increased prevalence in Parkinson's disease (PD). The aim of this review is to identify treatments available for patients suffering from ICDs, DDS and punding in PD. Searches of The Cochrane Controlled Trials Register, Embase, Medline and PsychInfo were conducted, using the entire timescale available. Seven out of the 688 papers retrieved met the inclusion criteria and were considered in this systematic review. One class I study, one class II study, and five class IV studies were identified. All studies demonstrated a positive effect on ICDs in PD. Research in this field is still in its early stages. At present, there is insufficient evidence to recommend any treatment over another. There is a need for more methodologically robust research, using larger, more generalizable samples, randomisation and meaningful follow-up periods. Additionally, the use of a validated outcome measures should be implemented in future research efforts.

show abstract

“…İkincil DP görülen hastalıklardan biri de, temel olarak nigrostriatal dopaminerjik yolaklarda işlev bozukluğu ile seyreden bir hastalık olan Parkinson hastalığıdır (PH). PH'nin klinik tabloya hakim olan motor belirtilerinin yanı sıra, depresyon, psikoz, otonomik işlev bozukluğu gibi motor olmayan belirtileri de mevcuttur (4).…”

unclassified

Parkinson hastalığı ve delüzyonel parazitoz birlikteliği: Bir olgu sunumu / Comorbidity of Parkinson’s disease and delusional parasitosis: a case report

Erdoğan¹,

Genç²,

Celikel³

et al. 2012

Dusunen Adam

View full text Add to dashboard Cite

ÖZETParkinson hastalığı ve delüzyonel parazitoz birlikteliği: Bir olgu sunumu Delüzyonel parazitoz kişide, vücudunun parazitler ya da küçük canlılar tarafından sarıldığına dair hatalı ve değiş-tirilemez bir inancın olduğu, az rastlanılan psikiyatrik bir hastalıktır. Her ne kadar her yaşta delüzyonel parazitoz görülebilse de, bazı araştırmalar yaşla birlikte, özellikle kadın cinsiyetinde görülme sıklığının arttığını öne sür-mektedir. Hastalık, genellikle birincil ve ikincil delüzyonel parazitoz olarak sınıflandırılmaktadır. İlki, saptanabilen herhangi bir hastalık sebebi olmayan hastaları kapsarken, ikincil delüzyonel parazitoz grubu genel organik durumla, diğer psikiyatrik hastalıklarla ve bazı maddelerle ilişkilidir. Bu olgu bildiriminde, 15 yıllık Parkinson hastalığı öyküsü bulunan 57 yaşında bir kadın hasta sunulmaktadır. Hastanın, vücudunun parazitler tarafından sarıldı-ğı düşüncesine sahip olduğu, psikiyatrik görüşme sırasında fark edilmiştir. Bu yazıda, Parkinson hastalığı ve delüzyonel parazitoz birlikteliği tartışılmaktadır. Anahtar kelimeler: Delüzyonel parazitoz, Parkinson hastalığı, dopamin ABSTRACT Comorbidity of Parkinson's disease and delusional parasitosis: a case reportDelusional parasitosis is a rare psychiatric disorder in which a person has the false and persistent belief of being infested with parasites or small living creatures. Although delusional parasitosis may occur at any age, some researchers suggest an increase in frequency in the elderly, especially in women gender. The disorder usually classified as primary and secondary delusional parasitosis. The first one contains patients without a detectable cause while the secondary delusional parasitosis group is associated with general organic conditions, other psychiatric illnesses and some drugs. In this case report, we present a 57 years-old woman who has Parkinson's disease for 15 years. Her psychiatric interview revealed her persistent thoughts about being infested by parasites. In this paper, we discussed delusional parasitosis comorbidity in Parkinson's disease.

show abstract

Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease

Cited by 65 publications

References 133 publications

Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa

Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa

A systematic review of treatments for Impulse Control Disorders and related behaviours in Parkinson׳s disease

Parkinson hastalığı ve delüzyonel parazitoz birlikteliği: Bir olgu sunumu / Comorbidity of Parkinson’s disease and delusional parasitosis: a case report

Contact Info

Product

Resources

About